SCHEMBL25754230

SCHEMBL25754230

CC#CC(O)CCCCCOCCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.44
HTT P42858 3/20 0.43
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
KMT2A Q03164 1/20 0.41
SPHK1 Q9NYA1 3/20 0.40
LPAR5 Q9H1C0 1/20 0.38
TSHR P16473 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.35
CES2 O00748 1/20 0.35
SPHK2 Q9NRA0 1/20 0.35
HMGCR P04035 1/20 0.35
CYP2D6 P10635 2/20 0.34
GMNN O75496 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754224 0.89 HTT (0.48) USP2HTTMAPTMEN1THRB
SCHEMBL25754242 0.86 USP2 (0.49) USP2HTTMAPTMEN1THRB
SCHEMBL25754236 0.86 HTT (0.33) USP2HTTMAPTMEN1THRB
SCHEMBL6466390 0.82 SPHK1 (0.50) HTTMAPTSPHK1CYP1A2CYP3A4
SCHEMBL28339798 0.82 SPHK1 (0.50) HTTMAPTSPHK1CYP1A2CYP3A4
SCHEMBL10617834 0.82 SPHK1 (0.50) HTTMAPTSPHK1CYP1A2CYP3A4
SCHEMBL8836714 0.82 SPHK1 (0.50) HTTMAPTSPHK1CYP1A2CYP3A4
SCHEMBL25754247 0.81 USP2 (0.51) USP2HTTMAPTMEN1THRB
SCHEMBL25754243 0.81 USP2 (0.51) USP2HTTMAPTMEN1THRB
SCHEMBL26632829 0.80 SPHK1 (0.46) HTTMAPTSPHK1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 USP2 51/4885HTT 916/4885MAPT 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.